Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A

SSZSE:301211
10.15
CNY
-0.33
(-3.15%)
0.13EPS
101.45P/E
5.30BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.30B, placing it among publicly traded companies globally. Its enterprise value stands at 3.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.30B
Enterprise Value3.79B

Share Statistics

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A has 417.60M shares outstanding.

Shares Outstanding417.60M

Valuation Ratios

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 101.45. The price-to-sales ratio is 11.13, and the price-to-book ratio stands at 2.32.

PE Ratio101.45
PS Ratio11.13
PB Ratio2.32
P/TBV Ratio2.39

Enterprise Valuation

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 62.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 62.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.79B versus a market cap of 5.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.75
EV / EBITDA62.03
EV / EBIT62.03

Financial Position

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A maintains a current ratio of 19.49, meaning it holds 19.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.07, indicating conservative leverage, while an interest coverage ratio of 521.86 demonstrates strong ability to service its debt obligations.

Current Ratio19.49
Quick Ratio16.62
Debt / Equity0.07
Debt / EBITDA0.03
Interest Coverage521.86

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 2.36, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.36 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.36, useful for judging operating efficiency across full business cycles. The company generates approximately 495,274.08 in revenue per employee across its workforce of 987.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.89 indicates how many times Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)2.36
Return on Assets (ROA)2.24
Return on Invested Capital (ROIC)2.36
Return on Capital Employed (ROCE)2.36
Revenue Per Employee495,274.08
Employee Count987.00
Inventory Turnover2.89

Taxes

CNY

Over the twelve months ended September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A recorded 7.33M in income tax expense. That works out to an effective tax rate of 12.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 60.97M, leaving 53.64M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax7.33M
Effective Tax Rate12.03

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A's stock has declined approximately 31.19% over the past 52 weeks. The 50-day moving average sits at 11.45, while the 200-day moving average is 11.63.

52-Week Price Change-31.19%
50-Day Moving Average11.45
200-Day Moving Average11.63

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A generated 488.84M in revenue and converted that into 53.64M in net income, yielding earnings per share of 0.13. EBITDA reached 61.10M, while operating income came in at 30.15M.

Revenue488.84M
Gross Profit116.95M
Operating Income30.15M
Pretax Income60.97M
Net Income53.64M
EBITDA61.10M
EBIT61.10M
Earnings Per Share (EPS)0.13

Balance Sheet

CNY

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A holds 1.52B in cash and equivalents against 1.54M in total debt, resulting in a net debt position of -385.51M. Total book value stands at 2.29B, with working capital of 1.69B providing operational flexibility.

Cash & Cash Equivalents1.52B
Total Debt1.54M
Net Debt-385.51M
Equity (Book Value)2.29B
Book Value Per Share5.48
Working Capital1.69B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-64.37M

Margins

Over the twelve months ended September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A posted a gross margin of 23.92, reflecting its pricing power and cost economics. The operating margin of 6.17 and net profit margin of 10.97 provide insight into operational efficiency.

Gross Margin23.92
Operating Margin6.17
Pretax Margin12.47
Profit Margin10.97
EBITDA Margin12.50

Stock Splits

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A's most recent stock split took place on August 27, 2025 with a 20:29 split ratio.

Last Split Date8/27/2025
Split Ratio20:29

Scores

As of September 30, 2026, Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 31.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score31.93